TG Therapeutics Q2 net loss $40.5M, down from $78.5M YoY; cash $231.8M

TG THERAPEUTICS, INC.

2022-Q2 EPS reported -$0.81 revenue$2,610,000

Net loss of $40.5M in Q2 2022 vs $78.5M in Q2 2021; six-month loss $109.5M vs $169.1M.
R&D expenses $26.9M (Q2 2022) vs $44.9M (Q2 2021), down on cost-saving measures and UKONIQ withdrawal.
Cash & investments $231.8M at June 30, 2022; expected to fund operations into H2 2023.
PDUFA goal date for ublituximab in RMS set for December 28, 2022; preparing for potential early 2023 launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.